Skip to main content

Table 1 Summary of patient characteristics

From: Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

 Total
n = 962
BRIM2
n = 132
BRIM3
n = 337
coBRIM
n = 493
Treatment
 Vemurafenib monotherapy715 (74%)132 (100%)337 (100%)246 (50%)
 Vemurafenib + cobimetinib247 (26%)0 (0%)0 (0%)247 (50%)
Sex
 Male565 (59%)81 (61%)200 (59%)284 (58%)
 Female397 (41%)51 (39%)137 (41%)209 (42%)
Age (years)
 Median (IQR)55 (45–65)52 (40–63)56 (47–65)55 (45–66)
Race
 White923 (96%)130 (98%)333 (99%)460 (93%)
 Other14 (1%)2 (2%)4 (1%)8 (2%)
 Missing25 (3%)0 (0%)0 (0%)25 (5%)
BRAF V600 mutation
 V600E762 (79%)122 (92%)296 (88%)344 (70%)
 V600K98 (10%)10 (8%)33 (10%)55 (11%)
 Missing102 (11%)0 (0%)8 (2%)94 (19%)
Stage
 Unresectable IIIc54 (6%)0 (0%)20 (6%)34 (7%)
 M1a146 (15%)33 (25%)33 (10%)80 (16%)
 M1b162 (17%)18 (14%)62 (18%)82 (17%)
 M1c599 (62%)80 (61%)222 (66%)297 (60%)
 Missing1 (< 1%)1 (1%)0 (0%)0 (0%)
ECOG PS
 0639 (66%)61 (46%)230 (68%)348 (71%)
  > 0317 (33%)71 (54%)107 (32%)139 (28%)
 Missing6 (1%)0 (0%)0 (0%)6 (1%)
Weight (kg)
 Median (IQR)78 (66–91)76 (65–92)79 (66–89)78 (67–92)
 Missing7 (1%)0 (0%)4 (1%)3 (1%)
  1. ECOG PS Eastern Cooperative Oncology Group performance status, IQR interquartile range